Bao Pharma-B Completes HK$1.99 Million Share Buyback, Outstanding Shares Fall to 152.29 Million

Bulletin Express09-01

Shanghai Bao Pharmaceuticals Co., Ltd. (Bao Pharma-B) disclosed that it repurchased 119,200 H-shares on 1 September 2026 via on-exchange transactions, paying an aggregate HK$1.99 million. The shares were bought at prices ranging between HK$16.48 and HK$16.81, implying a volume-weighted average cost of HK$16.73 per share.

Following the transaction, the company’s issued share capital (excluding treasury shares) decreased by 0.08% to 152.29 million shares. Concurrently, treasury stock rose to 2.04 million shares, while the total number of issued shares remained unchanged at 154.33 million.

The repurchase forms part of the 10% buyback mandate approved on 26 May 2026, which authorises the company to acquire up to 15.43 million shares. Cumulative repurchases under this mandate now stand at 2.04 million shares, representing 1.32% of the share count recorded on the mandate date.

Under Hong Kong listing rules, Bao Pharma-B is restricted from issuing, selling or transferring treasury shares for 30 days following the latest repurchase, setting the moratorium’s expiry on 1 October 2026.

Executive Director Liu Yanjun confirmed that all repurchases were executed in accordance with Hong Kong Stock Exchange requirements and the company’s stated repurchase programme.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/1100111680?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-09-01 18:21","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1100111680","market":"hk","top_or_hot":-1,"title":"Bao Pharma-B Completes HK$1.99 Million Share Buyback, Outstanding Shares Fall to 152.29 Million","media":"Bulletin Express","content":"<p>Shanghai Bao Pharmaceuticals Co., Ltd. (Bao Pharma-B) disclosed that it repurchased 119,200 H-shares on 1 September 2026 via on-exchange transactions, paying an aggregate HK$1.99 million. The shares were bought at prices ranging between HK$16.48 and HK$16.81, implying a volume-weighted average cost of HK$16.73 per share.</p>\n<p>Following the transaction, the company’s issued share capital (excluding treasury shares) decreased by 0.08% to 152.29 million shares. Concurrently, treasury stock rose to 2.04 million shares, while the total number of issued shares remained unchanged at 154.33 million.</p>\n<p>The repurchase forms part of the 10% buyback mandate approved on 26 May 2026, which authorises the company to acquire up to 15.43 million shares. Cumulative repurchases under this mandate now stand at 2.04 million shares, representing 1.32% of the share count recorded on the mandate date.</p>\n<p>Under Hong Kong listing rules, Bao Pharma-B is restricted from issuing, selling or transferring treasury shares for 30 days following the latest repurchase, setting the moratorium’s expiry on 1 October 2026.</p>\n<p>Executive Director Liu Yanjun confirmed that all repurchases were executed in accordance with Hong Kong Stock Exchange requirements and the company’s stated repurchase programme.</p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Bao Pharma-B Completes HK$1.99 Million Share Buyback, Outstanding Shares Fall to 152.29 Million</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nBao Pharma-B Completes HK$1.99 Million Share Buyback, Outstanding Shares Fall to 152.29 Million\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1053168898\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/ed558ed0402cbe7d1ef4d150458f2b2e);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Bulletin Express </p>\n<p class=\"h-time\">2026-09-01 18:21</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>Shanghai Bao Pharmaceuticals Co., Ltd. (Bao Pharma-B) disclosed that it repurchased 119,200 H-shares on 1 September 2026 via on-exchange transactions, paying an aggregate HK$1.99 million. The shares were bought at prices ranging between HK$16.48 and HK$16.81, implying a volume-weighted average cost of HK$16.73 per share.</p>\n<p>Following the transaction, the company’s issued share capital (excluding treasury shares) decreased by 0.08% to 152.29 million shares. Concurrently, treasury stock rose to 2.04 million shares, while the total number of issued shares remained unchanged at 154.33 million.</p>\n<p>The repurchase forms part of the 10% buyback mandate approved on 26 May 2026, which authorises the company to acquire up to 15.43 million shares. Cumulative repurchases under this mandate now stand at 2.04 million shares, representing 1.32% of the share count recorded on the mandate date.</p>\n<p>Under Hong Kong listing rules, Bao Pharma-B is restricted from issuing, selling or transferring treasury shares for 30 days following the latest repurchase, setting the moratorium’s expiry on 1 October 2026.</p>\n<p>Executive Director Liu Yanjun confirmed that all repurchases were executed in accordance with Hong Kong Stock Exchange requirements and the company’s stated repurchase programme.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"02659","symbol_name":"宝济药业-B","start_time":0,"source_url":"","article_id":"1100111680","we_media_id":"1053168898","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1100111680","pubTimestamp":1788258102,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Bulletin Express","introduction":"Full Coverage of HK & US Stock Announcements","home_visible":1,"id":"1053168898","head_image":"https://community-static.tradeup.com/news/ed558ed0402cbe7d1ef4d150458f2b2e"},"summary":"Shanghai Bao Pharmaceuticals Co., Ltd. (Bao Pharma-B) disclosed that it repurchased 119,200 H-shares on 1 September 2026 via on-exchange transactions, paying an aggregate HK$1.99 million. The shares...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"02659":"宝济药业-B"},"translate_title":"宝医药B完成199万港元股份回购，流通股降至1.5229亿股","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"02659":1},"content_text":"Shanghai Bao Pharmaceuticals Co., Ltd. (Bao Pharma-B) disclosed that it repurchased 119,200 H-shares on 1 September 2026 via on-exchange transactions, paying an aggregate HK$1.99 million. The shares were bought at prices ranging between HK$16.48 and HK$16.81, implying a volume-weighted average cost of HK$16.73 per share.\nFollowing the transaction, the company’s issued share capital (excluding treasury shares) decreased by 0.08% to 152.29 million shares. Concurrently, treasury stock rose to 2.04 million shares, while the total number of issued shares remained unchanged at 154.33 million.\nThe repurchase forms part of the 10% buyback mandate approved on 26 May 2026, which authorises the company to acquire up to 15.43 million shares. Cumulative repurchases under this mandate now stand at 2.04 million shares, representing 1.32% of the share count recorded on the mandate date.\nUnder Hong Kong listing rules, Bao Pharma-B is restricted from issuing, selling or transferring treasury shares for 30 days following the latest repurchase, setting the moratorium’s expiry on 1 October 2026.\nExecutive Director Liu Yanjun confirmed that all repurchases were executed in accordance with Hong Kong Stock Exchange requirements and the company’s stated repurchase programme.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":true,"editions":null,"column":"","sentiment":"1","news_tag":"shareholding,SGX","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"isLaohu8Offline":false,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.49.0","shortVersion":"4.49.0","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/1100111680","isCrawlerRequest":true}